ArticleResearch square2026
Extended difficulties after psychedelic experiences: Prevalence and associations in a global, multilingual sample.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
As psychedelic use increases and integrates with mainstream medicine, understanding the prevalence and nature of postpsychedelic adverse outcomes is critical. We investigated extended difficulties after psychedelic use via the Global Psychedelic Survey (GPS) 2025, which is a multilingual online survey of people who have used psychedelics. Data on the prevalence, characteristics, and associations of retrospectively reported extended difficulties was gained from N = 6,476 participants. The most common difficulties reported were existential struggle (36.6%), depression (34%), and derealization (29.4%). Existential struggle was rated as the most severe difficulty, but also the one contributing most to healing. Overall, 48.3% of participants reported one or more difficulties lasting 24 hours or more, and 9.9% experienced difficulties for over a year. Clinically relevant disruptive difficulties (defined as leasting at least a month that caused disruption to daily life) were reported by 8% of the sample and were associated with younger age at the time of survey and at first psychedelic use, lower income, lack of family support, lower emotional stability/conscientiousness/agreeableness, higher pre-existing anxiety/depression, and using psychedelics to treat mental health conditions. The results underscore the necessity for evidence-based education on the potential risks and benefits of psychedelics, robust safety guidelines in clinical psychedelic interventions, and additional services for those experiencing post-psychedelic extended difficulties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.